Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?

Bristol Myers Squibb trades at just under 10x forward earnings and offers a forward dividend yield near 4%, with a payout ratio of roughly 40% and nearly 20 years of dividend growth. The company faces significant patent-cliff risk, including U.S. exclusivity losses for Eliquis and Opdivo in 2028; analysts expect EPS to decline to $6.56 next year from $6.95. Management is pursuing cost reductions and smaller acquisitions in cardiovascular, immunology, and oncology, which the article argues could support a continued recovery after shares rose nearly 35% since September 2025.

Analysis

BMY’s valuation discount is unlikely to close simply because the dividend appears covered: the market is underwriting a multi-year erosion in its highest-return revenue pool and assigning limited credit to acquired assets until they demonstrate durable, differentiated sales trajectories. The relevant rerating catalyst is not further cost reduction—largely a one-time offset—but evidence that new-product growth can exceed the legacy-franchise decline while preserving operating margin. Over the next 1-3 months, consensus EPS revisions and management’s 2027/2028 revenue-bridge disclosures matter more than the yield narrative.

The key second-order issue is capital allocation. Smaller acquisitions can improve pipeline breadth, but they also increase integration, milestone-payment, and post-deal commercial-execution risk precisely when BMY needs financial flexibility to defend its dividend and fund launches. AZN is a useful relative benchmark: its oncology platform has stronger perceived organic durability and therefore deserves a premium multiple; a BMY rerating requires narrowing that perceived quality gap, not merely remaining cheap.

Contrarianly, the low multiple may already discount more than a normal loss-of-exclusivity cycle if management can sustain the payout and replace even a modest portion of lost franchise economics. But income buyers may be the marginal holder rather than the marginal price setter; a dividend that is technically covered does not prevent multiple compression if 2028 earnings-power estimates reset lower. This is a 6-18 month execution trade, not a near-term catalyst-driven value realization.

Key Decisions for Investors

• Maintain BMY as a small income/value position only; do not chase recent strength. Add on a pullback only if updated guidance shows new-product revenue growth covering at least the incremental legacy-product decline, with no reduction in dividend-growth commitment.
• Use a relative-value framework: long BMY / short AZN only after BMY’s forward EPS estimates stabilize for two consecutive revision cycles. Target a partial compression of the valuation gap over 6-12 months; exit if BMY guides to a material 2028 earnings decline beyond current expectations or raises leverage to fund another acquisition.
• For existing BMY longs, buy 6-12 month downside protection around the next full-year guidance update rather than selling the equity outright. The primary downside catalyst is a weak launch trajectory or adverse U.S. pricing/reimbursement signal, which would turn the current payout narrative into a multiple-compression event.
• Set an earnings watch item for gross-margin and SG&A trends: if cost savings are masking weaker underlying demand and operating margin declines despite restructuring, reduce exposure. A sustained margin decline would falsify the thesis that acquisitions and efficiency measures can bridge the patent-expiry period.